What is Catalyst OrthoScience?
Founded in 2014 by orthopedic surgeon Dr. Steven Goldberg and headquartered in Naples, Florida, Catalyst OrthoScience is dedicated to advancing shoulder replacement surgery. The company's core innovation lies in its less invasive surgical techniques, designed to minimize complications and enhance the natural feel of the shoulder, setting it apart from conventional methods. Catalyst's total shoulder systems are engineered for superior precision and operational efficiency, focusing on the preservation of bone and soft tissue to achieve consistent and reproducible patient outcomes. With a robust portfolio of patents, the company's technology is currently accessible across the United States, signaling a strong market presence and a commitment to innovation in orthopedic care.
How much funding has Catalyst OrthoScience raised?
Catalyst OrthoScience has raised a total of $40.2M across 5 funding rounds:
Debt
$350K
Debt
$713K
Other Financing Round
$20M
Private Equity
$4.1M
Debt
$15M
Debt (2020): $350K with participation from PPP
Debt (2021): $713K led by PPP
Other Financing Round (2024): $20M supported by Bridge Bank, RC Capital, and Mutual Capital Partners
Private Equity (2025): $4.1M, investors not publicly disclosed
Debt (2025): $15M backed by Western Alliance Bank, RC Capital, and Mutual Capital Partners
Key Investors in Catalyst OrthoScience
Bridge Bank
Bridge Bank is a financial institution operating within the banking sector, providing a range of financial products and services. Its involvement suggests a strategic financial partnership to support Catalyst OrthoScience's growth initiatives.
RC Capital
RC Capital is a growth equity firm specializing in high-potential healthcare companies, particularly in medical devices and healthcare IT. Their investment indicates a belief in Catalyst OrthoScience's innovative approach to orthopedic surgery and its potential for market disruption.
Mutual Capital Partners
Mutual Capital Partners is a venture capital fund focused on early-stage software and medical device companies. Their backing of Catalyst OrthoScience highlights the company's innovative technology and its potential for significant impact within the medical device industry.
What's next for Catalyst OrthoScience?
The substantial enterprise-level funding and recent strategic investment indicate Catalyst OrthoScience is poised for significant scaling and further development. This capital infusion will likely fuel expanded market penetration, continued research and development into next-generation orthopedic solutions, and potentially strategic partnerships. The company's focus on patented, less invasive techniques positions it for continued growth in the competitive orthopedic device market, aiming to capture a larger share by offering superior patient outcomes and surgeon efficiency.
See full Catalyst OrthoScience company page
